Epratuzumab for Systemic Lupus Erythematosus
Authors:
- 3 April 2013
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 22 (4) , 400-405
Abstract
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). An overview of its mechanism of action is followed by a summary of completed lupus studies, and a preview of studies in progress. The agent clearly has anti-inflammatory activity and is a potentially useful agent in the management of autoimmune disorders.Keywords
This publication has 24 references indexed in Scilit:
- Treatment of systemic lupus erythematosus with epratuzumabBritish Journal of Clinical Pharmacology, 2011
- Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusArthritis Research & Therapy, 2010
- CD20‐depleting therapy in autoimmune diseases: from basic research to the clinicJournal of Internal Medicine, 2010
- B cells in autoimmunityArthritis Research & Therapy, 2009
- Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controlsAnnals of the Rheumatic Diseases, 2008
- Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- A Role in B Cell Activation for CD22 and the Protein Tyrosine Phosphatase SHPScience, 1995
- Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.Journal of Experimental Medicine, 1995
- Internalization and intracellular processing of an anti B‐cell lymphoma monoclonal antibody, ll2International Journal of Cancer, 1994
- cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.Journal of Experimental Medicine, 1991